A2 Biotherapeutics is a startup. 1 investor tracked. Status: possibledead.
A2 Biotherapeutics is a startup founded in 2016 based in the United States. Its most recent tracked round is Series-c-plus. Brouky records 3 investors associated with the company.
A2 Biotherapeutics develops precision cell therapies using its Tmod™ platform to selectively target and destroy tumor cells while sparing normal cells, addressing the challenge of distinguishing tumor cells from healthy ones in solid tumor cancers.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.